trending Market Intelligence /marketintelligence/en/news-insights/trending/zWOulMWAeHW5tN7OPHlEGw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Protagonist Therapeutics prices stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Protagonist Therapeutics prices stock offering

Protagonist Therapeutics Inc. priced its underwritten public offering of 3,530,000 shares at $17.00 per share.

The company expects to raise a total of about $60.0 million in gross proceeds from the offering, before underwriting discounts and commissions and offering costs.

Protagonist Therapeutics granted the underwriters a 30-day option to purchase up to an additional 529,500 shares.

The Calif.-based biopharmaceutical company intends to use net proceeds to fund clinical research and development of three therapeutic candidates including the completion of ongoing clinical trials, discovery programs and platform development, and for working capital and general corporate purposes.

The offering is expected to close on or about Oct. 16, subject to customary closing conditions.